CSS LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

CSS LLC’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20,000	Closed	-$234K	–	825
2023 Q3	$234K	Buy	+20,000	New	+$268K	0.02%	575

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

CSS LLC's CPRX Position: Q4 2023 in Review

CSS LLC sold out of Catalyst Pharmaceutical (CPRX) in Q4 2023, closing a stake of 20,000 shares — an estimated $234K sold.

CSS LLC first reported a position in CPRX in Q3 2023 and held it in 1 quarter. The position peaked at $234K in Q3 2023. 259 funds tracked by Wall St. Rank hold CPRX as of Q4 2023.

CSS LLC reported no remaining Catalyst Pharmaceutical position as of Q4 2023 after selling out during the quarter.
CSS LLC sold 20,000 Catalyst Pharmaceutical shares in Q4 2023, an estimated $234K.
CSS LLC first reported a position in Catalyst Pharmaceutical in Q3 2023 and held it in 1 quarter.
CSS LLC's Catalyst Pharmaceutical position peaked at $234K in Q3 2023.
259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2023.

Based on CSS LLC's 13F filing for Q4 2023, filed 14 Feb 2024.